Scott Biggs, Director of Supplier Services at IQVIA, discussed pharmacy trends within the industry and how pharmacists can stay ahead of them.
At the Fall 2024 Total Pharmacy Solutions Summit, held virtually on October 19, Scott Biggs, Director of Supplier Services at IQVIA, discussed various pharmacy trends including the US Use of Medicine Report, retail pharmacy performance, booming medications like GLP-1s, and much more. Keeping their hand on the pulse of pharmacy, the team at IQVIA and InterLink AI put together this presentation to also help independent pharmacists stay ahead of the curve.
“We know that there are a lot of challenges out there in this industry,” said Biggs. “In the end, all these challenges that we’re facing impact the patients.” From drug shortages and issues surrounding biosimilars to DSCSA stabilization and DIR fees, everyday patients may not understand the common challenges pharmacies face. Furthermore, patients don’t understand how pharmacy challenges—when they’re not addressed—fall onto them and ultimately impact their overall health outcomes.
Every Spring, IQVIA presents the US Health Services Utilization Index. Biggs touched on his company’s resource and how it helps pharmacists understand the prescriptions they fill in the pharmacy to a fuller capacity. He used the US Health Services Utilization Index to dive deep into trends within pharmacy, from vaccine uptake to GLP-1 medications.
Check out Biggs’ presentation titled “Leveraging US Prescription Market Insights to Drive Pharmacy Innovation” from the Fall 2024 Total Pharmacy Solutions Summit. Learn more about pharmacy trends, how to stay more on top of them, and how data and technology can translate to more revenue at the pharmacy counter.
Explore more of our coverage from the Total Pharmacy Solutions Summit Fall 2024: Innovating with Cutting-Edge Technology.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.